Gilead Sciences (GILD) Prepaid Assets (2009 - 2026)
Gilead Sciences (GILD) reported Prepaid Assets of $4.3 billion for Q1 2026, up 53.54% on a YoY basis from $2.8 billion in Q1 2025, and up 7.9% quarter-over-quarter from $4.0 billion in Q4 2025.
Gilead Sciences (GILD) Prepaid Assets (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Prepaid Assets for 18 years, with the latest figure at $4.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 53.54% year-over-year to $4.3 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 53.54% YoY), and the FY2025 full-year result was $4.0 billion, up 31.85% from the prior year.
- Prepaid Assets for Q1 2026 stood at $4.3 billion, up from $4.0 billion in the prior quarter.
- The five-year high for Prepaid Assets was $4.3 billion in Q1 2026, with the low at $1.8 billion in Q2 2023.
- Historically, Prepaid Assets has averaged $2.7 billion across 5 years, with a median of $2.8 billion in 2024.
- Annual changes were most pronounced in 2022 — Prepaid Assets fell 17.14% — and 2024, when it soared 62.55%.
- Gilead Sciences' Prepaid Assets stood at $1.8 billion in 2022, then soared by 33.82% to $2.4 billion in 2023, then increased by 28.56% to $3.1 billion in 2024, then soared by 31.85% to $4.0 billion in 2025, then advanced by 7.9% to $4.3 billion in 2026.
- The last three Prepaid Assets figures came in at $4.3 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.34 Bn |
| Dec 31, 2025 | 4.02 Bn |
| Sep 30, 2025 | 3.65 Bn |
| Jun 30, 2025 | 2.90 Bn |
| Mar 31, 2025 | 2.83 Bn |
| Dec 31, 2024 | 3.05 Bn |
| Sep 30, 2024 | 3.29 Bn |
| Jun 30, 2024 | 2.86 Bn |
| Mar 31, 2024 | 2.80 Bn |
| Dec 31, 2023 | 2.37 Bn |
| Sep 30, 2023 | 2.66 Bn |
| Jun 30, 2023 | 1.76 Bn |
| Mar 31, 2023 | 1.85 Bn |
| Dec 31, 2022 | 1.77 Bn |
| Sep 30, 2022 | 2.08 Bn |
| Jun 30, 2022 | 1.90 Bn |
| Mar 31, 2022 | 2.04 Bn |
| Dec 31, 2021 | 2.14 Bn |
| Sep 30, 2021 | 2.01 Bn |
| Jun 30, 2021 | 1.48 Bn |